Clinical Grant Expenditures are Stabilizing
Site per visit increases have been smaller in recent years.
Site per visit increases have been smaller in recent years. To a large extent this may be a function of the number of sites that are being opened in non-traditional, less expensive geographies. According to GrantPlan® and ClinicalTrials.gov, a growing number of clinical studies are using sites in areas such as Latin America, Asia, and Eastern Europe. In addition, the total number of new sites opened in the last 12 months around the world has been fairly constant. The recent relatively flat overall increased demand for sites, coupled with the continued shift of clinical trial work to less expensive geographies have combined to reduce the demand for clinical investigators. Consequently, sites around the world have less ability to command higher prices.
Mean cost per visit in Phase II-III clinical trials.
GrantPlan subscribers conduct nearly 80% of all commercial clinical trials around the world, with each company contributing the active grant agreements to the database. On a cost per visit basis, site costs have risen or stayed relatively flat in the various major geographies for conducting clinical trials. The United States continues to be the most expensive country in which to conduct clinical trials, followed by the United Kingdom and Western Europe. Just as importantly, the difference in per visit costs between the traditional and newer geographies continues to exist. Latin America, Asia, and Eastern Europe continue be lower priced areas for clinical grants.
—TTC (for more information, contact help@ttc-llc.com
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
